Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03750565 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Ethnobridging PK Study in Healthy Subjects
A Phase 1 study of Inflammatory Bowel Diseases and IBD, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03750565 is a Phase 1 study of Inflammatory Bowel Diseases and IBD that has completed, run by Theravance Biopharma. The registered enrollment target is 60 participants, below the 42,260-participant average among 48 other Inflammatory Bowel Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03750565, a Phase 1 study of Inflammatory Bowel Diseases and IBD, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 1, double blind, placebo controlled, 4 cohort, multiple dose study in healthy adult Japanese and Caucasian subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TD-1473 - Dose A
- DRUG TD-1473 - Dose B
- DRUG TD-1473 - Dose C
Study Locations (1)
California
- Theravance Biopharma Investigational Site - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2019-02-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03750565
The ClinicalTrials.gov registry entry for NCT03750565 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 42,260-participant average among 48 other Inflammatory Bowel Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Inflammatory Bowel Diseases appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03750565 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03750565 about?
NCT03750565 is a clinical study titled "Multiple Dose Ethnobridging PK Study in Healthy Subjects". A Phase 1, double blind, placebo controlled, 4 cohort, multiple dose study in healthy adult Japanese and Caucasian subjects.
What is the current status of trial NCT03750565?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2018-11-27. Estimated completion is 2019-02-13.
What conditions does trial NCT03750565 study?
This clinical trial studies the following conditions: Inflammatory Bowel Diseases, IBD.
What interventions are being tested in trial NCT03750565?
The interventions under investigation include: Placebo (DRUG), TD-1473 - Dose A (DRUG), TD-1473 - Dose B (DRUG), TD-1473 - Dose C (DRUG).
Who is sponsoring clinical trial NCT03750565?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03750565 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammatory Bowel Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Beta-Hydroxybutyrate Feasibility Treating IBD
RECRUITING · Phase 1
-
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
RECRUITING · Phase 1
-
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
COMPLETED · Phase 1
-
Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis
COMPLETED · Phase 1
-
Pre-operative Nutrition for Elective Resection Surgery in Inflammatory Bowel Disease
RECRUITING · NA
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.